# OnCo record checkmate-227 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/checkmate-227/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "checkmate-227", "NCT02477826" ;
  schema:name "CheckMate 227"@en ;
  schema:description "CheckMate 227 showed that a chemotherapy-free pair of immunotherapy drugs, nivolumab and ipilimumab, helped people with advanced lung cancer live longer than chemotherapy alone, which made it a first-line option for tumours with any PD-L1 expression."@en ;
  schema:url <https://onco.cc/trials/checkmate-227/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02477826> ;
  onco:status "positive" ;
  onco:tag "subtype-trials" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/pdl1-high-nsclc/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/lung-cancer/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/> ;
  onco:companies <https://onco.cc/companies/bms/> ;
  onco:people <https://onco.cc/people/matthew-hellmann/> .